Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR3 |
Variant | G372C |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | FGFR3 G372C (corresponds to G370C in the canonical isoform) lies within the extracellular domain of the Fgfr3 protein (UniProt.org). G372C confers a gain of function on Fgfr3, as indicated by ligand-independent phosphorylation and dimerization of Fgfr3, and activation of MAPK pathway in cell culture (PMID: 16841094, PMID: 12009017). |
Associated Drug Resistance | |
Category Variants Paths |
FGFR3 mutant FGFR3 act mut FGFR3 G372C |
Transcript | NM_022965.4 |
gDNA | chr4:g.1805392G>T |
cDNA | c.1114G>T |
Protein | p.G372C |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_006713868.1 | chr4:g.1804362G>T | c.1114G>T | p.G372C | RefSeq | GRCh38/hg38 |
XM_006713871.2 | chr4:g.1804362G>T | c.1114G>T | p.G372C | RefSeq | GRCh38/hg38 |
NM_022965.3 | chr4:g.1805392G>T | c.1114G>T | p.G372C | RefSeq | GRCh38/hg38 |
NM_001163213.1 | chr4:g.1804362G>T | c.1114G>T | p.G372C | RefSeq | GRCh38/hg38 |
XM_006713870 | chr4:g.1804362G>T | c.1114G>T | p.G372C | RefSeq | GRCh38/hg38 |
XM_006713870.2 | chr4:g.1804362G>T | c.1114G>T | p.G372C | RefSeq | GRCh38/hg38 |
XM_047449820.1 | chr4:g.1804362G>T | c.1114G>T | p.G372C | RefSeq | GRCh38/hg38 |
XM_006713868.2 | chr4:g.1804362G>T | c.1114G>T | p.G372C | RefSeq | GRCh38/hg38 |
NM_001163213.2 | chr4:g.1804362G>T | c.1114G>T | p.G372C | RefSeq | GRCh38/hg38 |
XM_006713871 | chr4:g.1804362G>T | c.1114G>T | p.G372C | RefSeq | GRCh38/hg38 |
XM_047449821.1 | chr4:g.1804362G>T | c.1114G>T | p.G372C | RefSeq | GRCh38/hg38 |
XM_006713869 | chr4:g.1804362G>T | c.1114G>T | p.G372C | RefSeq | GRCh38/hg38 |
NM_001163213 | chr4:g.1804362G>T | c.1114G>T | p.G372C | RefSeq | GRCh38/hg38 |
XM_006713869.1 | chr4:g.1804362G>T | c.1114G>T | p.G372C | RefSeq | GRCh38/hg38 |
XM_006713869.2 | chr4:g.1804362G>T | c.1114G>T | p.G372C | RefSeq | GRCh38/hg38 |
XM_006713868 | chr4:g.1804362G>T | c.1114G>T | p.G372C | RefSeq | GRCh38/hg38 |
XM_006713871.1 | chr4:g.1804362G>T | c.1114G>T | p.G372C | RefSeq | GRCh38/hg38 |
NM_022965 | chr4:g.1805392G>T | c.1114G>T | p.G372C | RefSeq | GRCh38/hg38 |
NM_022965.4 | chr4:g.1805392G>T | c.1114G>T | p.G372C | RefSeq | GRCh38/hg38 |
XM_006713870.1 | chr4:g.1804362G>T | c.1114G>T | p.G372C | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04972253 | Phase I | Infigratinib | Phase I BLASST-3 Trial ((BLASST)-3) | Withdrawn | 0 |